当前位置:首页 > 股票大全 > 拓新药业 301089 财务分析

拓新药业财务分析

整理编辑:168股票行情网www.gphq168.com    数据来源:互联网 经供参考

拓新药业(301089)利润表
报告期2024-03-312023-12-312023-09-302023-06-30
营业总收入108,322,506.68835,509,951.28746,127,863.8656,976,189.03
营业总成本111,604,696.36517,162,283.47366,447,775.5256,091,187.13
营业利润2,476,875.18321,683,932.11381,896,140.21397,619,903.88
利润总额2,452,205.56316,533,369.79379,615,109.46395,584,307.29
净利润2,068,381.83243,072,734.38313,190,833.52309,532,944.12
其他综合收益--2,126,356.94--
综合收益总额2,068,381.83240,946,377.44313,190,833.52309,532,944.12
拓新药业(301089)资产负债表
报告期2024-03-312023-12-312023-09-302023-06-30
流动资产合计785,429,083.52822,169,778.54916,161,811.86983,832,454.69
非流动资产合计1,033,439,375.711,016,824,783.44945,569,512.71905,775,539.24
资产总计1,818,868,459.231,838,994,561.981,861,731,324.571,889,607,993.93
流动负债合计172,287,885.78194,512,240.38149,354,356.17190,720,670.7
非流动负债合计41,240,323.0241,210,45340,534,842.3841,596,953.8
负债合计213,528,208.8235,722,693.38189,889,198.55232,317,624.5
归属于母公司股东权益合计1,605,340,250.431,603,271,868.61,671,842,126.021,657,290,369.43
股东权益合计1,605,340,250.431,603,271,868.61,671,842,126.021,657,290,369.43
负债和股东权益合计1,818,868,459.231,838,994,561.981,861,731,324.571,889,607,993.93
拓新药业(301089)现金流量表
报告期2024-03-312023-12-312023-09-302023-06-30
经营活动现金流入小计137,056,378.39690,399,431.17613,371,736.42502,814,750.66
经营活动现金流出小计84,910,887.82663,446,067.16560,780,143.53453,099,326.09
经营活动产生的现金流量净额52,145,490.5726,953,364.0152,591,592.8949,715,424.57
投资活动现金流入小计191,461,695.621,296,612,507.21,241,331,779.53803,555,841.42
投资活动现金流出小计85,429,006.71,425,220,153.311,215,798,785.26977,624,991.99
投资活动产生的现金流量净额106,032,688.92-128,607,646.1125,532,994.27-174,069,150.57
筹资活动现金流入小计-21,600,316.5--
筹资活动现金流出小计-90,672,638.8990,696,527.7890,696,527.78
筹资活动产生的现金流量净额--69,072,322.39-90,696,527.78-90,696,527.78
汇率变动对现金及现金等价物的影响256,793.38111,376.861,653.711,653.71
现金及现金等价物净增加额158,434,972.87-170,615,227.63-12,570,286.91-215,048,600.07
期末现金及现金等价物余额289,168,255.37130,733,282.5288,778,223.2286,299,910.06
拓新药业301089相关数据
今日股市大盘指数